- Home
- SYNX vs BCTX Comparison
SYNX vs BCTX Comparison
Compare SYNX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- BCTX
- Stock Information
- Founded
- SYNX 2005
- BCTX 2014
- Country
- SYNX Israel
- BCTX Canada
- Employees
- SYNX N/A
- BCTX N/A
- Industry
- SYNX
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- SYNX
- BCTX Health Care
- Exchange
- SYNX Nasdaq
- BCTX Nasdaq
- Market Cap
- SYNX 15.6M
- BCTX 17.2M
- IPO Year
- SYNX 2024
- BCTX N/A
- Fundamental
- Price
- SYNX $2.61
- BCTX $0.60
- Analyst Decision
- SYNX
- BCTX Strong Buy
- Analyst Count
- SYNX 0
- BCTX 1
- Target Price
- SYNX N/A
- BCTX $15.00
- AVG Volume (30 Days)
- SYNX 7.9K
- BCTX 948.2K
- Earning Date
- SYNX 11-26-2024
- BCTX 12-12-2024
- Dividend Yield
- SYNX N/A
- BCTX N/A
- EPS Growth
- SYNX N/A
- BCTX N/A
- EPS
- SYNX N/A
- BCTX N/A
- Revenue
- SYNX $9,893,000.00
- BCTX N/A
- Revenue This Year
- SYNX $52.34
- BCTX N/A
- Revenue Next Year
- SYNX N/A
- BCTX N/A
- P/E Ratio
- SYNX N/A
- BCTX N/A
- Revenue Growth
- SYNX 18.05
- BCTX N/A
- 52 Week Low
- SYNX $2.10
- BCTX $0.46
- 52 Week High
- SYNX $4.10
- BCTX $5.97
- Technical
- Relative Strength Index (RSI)
- SYNX 36.82
- BCTX 33.57
- Support Level
- SYNX $2.50
- BCTX $0.57
- Resistance Level
- SYNX $2.94
- BCTX $0.74
- Average True Range (ATR)
- SYNX 0.25
- BCTX 0.06
- MACD
- SYNX -0.01
- BCTX -0.02
- Stochastic Oscillator
- SYNX 33.90
- BCTX 7.58
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.